Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 food-effect and dosing strategy study in advanced solid tumors
2005-003441-13Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cediranib in Nonhematologic neoplasms (4 arms), sponsored by AstraZeneca. Primary endpoints: AUC and Cmax. Started Jan 2006; status: completed.
02
Drugs
cediranib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2005-003441-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003441-13.